Plain-English translation of NCT07222917 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether baxdrostat combined with dapagliflozin can better protect your kidneys than baxdrostat alone in people with chronic kidney disease and high blood pressure. The study will measure how much protein appears in your urine, which is a sign of kidney health. Researchers want to see if adding the second medication provides extra protection for your kidneys.
Many people with chronic kidney disease and high blood pressure still lose kidney function even when taking current treatments. This medication combination is being tested to see if it can slow down kidney damage and reduce protein loss in the urine better than existing options.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic multiple times over the course of the study for blood and urine tests to check your kidney function, blood pressure, and potassium levels. You would take one pill containing baxdrostat and another pill daily—either the second medication (dapagliflozin) or a placebo (dummy pill) depending on which group you are randomly assigned to. You won't know which group you're in, and neither will your doctors, until the study ends. The study involves visits at multiple centers and will last as long as needed to collect results from all participants.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
United States